LS-104 is a non-ATP-competitive inhibitor of JAK2, Bcr-Abl, and FLT3 kinases; it effectively induces apoptosis in JAK2V617F-positive cells, inhibits JAK2 autophosphorylation and downstream signaling, suppresses proliferation of FLT3-expressing leukemia cells, and exerts potent cytotoxic effects; it shows promise for the research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.